Product image of Methotrexaat Eugia (Methotrexate) supplied by GNH India

Methotrexaat Eugia

Active Ingredient:
Methotrexate
Origin:
EU

Methotrexaat Eugia (Methotrexate)

Methotrexate, the active ingredient in Methotrexaat Eugia, is an antimetabolite presented as an oral formulation for systemic use. It is employed in the management of several autoimmune and oncologic conditions, including rheumatoid arthritis, psoriasis, and certain leukemias and lymphomas. The drug interferes with folate metabolism, reducing cell proliferation.

GNH India supplies Methotrexaat Eugia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across regions.

Manufacturer / TM Owner

Eugia Pharma (Malta) Ltd

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Methotrexate acts on rapidly dividing cells and immune pathways, making it useful for a range of autoimmune and malignant diseases.

  • Rheumatoid arthritis: reduces joint inflammation and slows disease progression.
  • Psoriasis: diminishes skin plaque formation and severity.
  • Acute lymphoblastic leukemia: induces remission by inhibiting leukemic cell proliferation.
  • Non‑Hodgkin lymphoma: contributes to tumor control in combination regimens.
  • Gestational trophoblastic disease: promotes resolution of abnormal trophoblastic tissue.

How It Works

  • Methotrexate inhibits dihydrofolate reductase, blocking the conversion of dihydrofolate to tetrahydrofolate. This impairs synthesis of purine nucleotides and thymidylate, leading to reduced DNA replication and cell division, particularly in rapidly proliferating immune cells and malignant cells.

Side Effects

Methotrexate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Nausea or vomiting.
  • Fatigue or malaise.
  • Oral mucosal ulceration (stomatitis).
  • Elevated liver enzymes.
  • Mild to moderate bone marrow suppression (e.g., neutropenia, anemia).
  • Alopecia (hair thinning or loss).

Serious or Rare Side Effects

  • Severe hepatotoxicity or liver fibrosis.
  • Life‑threatening bone marrow failure (aplastic anemia).
  • Pulmonary toxicity, including interstitial pneumonitis.
  • Severe infections due to immunosuppression.
  • Renal impairment from crystal nephropathy.
  • Rare cutaneous reactions such as Stevens‑Johnson syndrome.

Precautions & Warnings

Methotrexate requires careful monitoring and specific safety measures.

  • Liver Monitoring: perform baseline and periodic liver function tests.
  • Hematologic Surveillance: regular complete blood counts to detect cytopenias.
  • Pregnancy Avoidance: contraindicated in pregnancy (Category X); ensure effective contraception.
  • Renal Function: adjust dosing or avoid use in significant renal impairment.
  • Drug Interactions: avoid concurrent use with NSAIDs or other hepatotoxic agents without supervision.
  • Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Methotrexate can interact with several medicines, altering its efficacy or toxicity.

Major Interactions (Avoid)

  • NSAIDs (e.g., ibuprofen, naproxen): increase risk of renal toxicity and myelosuppression.
  • Penicillins (e.g., ampicillin): may elevate methotrexate plasma levels.
  • Sulfonamides: potentiate hematologic toxicity.
  • Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

  • Warfarin: enhanced anticoagulant effect, monitor INR.
  • Proton pump inhibitors: may affect absorption and increase toxicity.
  • Trimethoprim‑sulfamethoxazole: monitor blood counts for additive myelosuppression.

Frequently Asked Questions

Methotrexaat Eugia contains methotrexate, which is prescribed for autoimmune diseases such as rheumatoid arthritis and psoriasis, as well as for certain cancers including acute lymphoblastic leukemia, non‑Hodgkin lymphoma, and gestational trophoblastic disease. The drug works by inhibiting cell proliferation in these conditions.

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA synthesis. This action reduces the replication of rapidly dividing cells, including immune cells that drive inflammation and malignant cells in various cancers.

The specific dose of Methotrexaat Eugia is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and treatment goals. Dosage regimens vary widely across indications and must be individualized by a qualified healthcare professional.

Methotrexaat Eugia is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also not recommended while breastfeeding because it can be excreted in milk and affect the infant.

To request Methotrexaat Eugia, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Methotrexaat Eugia (methotrexate) is a widely used antimetabolite with a broad therapeutic range, whereas alternatives like azathioprine or cyclophosphamide have different toxicity profiles and mechanisms. Methotrexate’s folate antagonism offers potent anti‑inflammatory and anti‑cancer effects but requires careful monitoring of liver and blood parameters.

Methotrexaat Eugia should be stored at or below 25 °C in its original packaging, protected from moisture and direct sunlight. Maintaining a stable ambient temperature helps preserve tablet integrity and potency throughout its shelf life.

Methotrexaat Eugia is supplied as an oral formulation and is taken by mouth with or without food, as directed by the prescribing clinician. The exact administration schedule—daily, weekly, or as part of a cycle—depends on the specific indication and patient response.

Serious risks include severe liver toxicity, bone marrow suppression leading to pancytopenia, pulmonary fibrosis or interstitial pneumonitis, and life‑threatening infections due to immunosuppression. Patients should be monitored regularly for signs of these complications and advised to report any concerning symptoms promptly.

Methotrexaat Eugia is contraindicated in pregnant women, individuals with severe liver disease, uncontrolled infections, or known hypersensitivity to methotrexate. Caution is also advised for patients with significant renal impairment or pre‑existing blood disorders, and it should be avoided in those receiving live vaccines.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Methotrexate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT